Hongsik Kim

Professor

Chungbuk National University Hospital

South Korea

Research Interests

Explore related searches

Professors in South Korea Professors in Immunology Immunology professors in South Korea

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Hongsik Kim is a Professor at Chungbuk National University Hospital in South Korea. His research focuses on various aspects of oncology, including the differential diagnosis of carcinomas, treatment outcomes for hepatocellular carcinoma, and the therapeutic effects of innovative treatments for chemotherapy-related side effects. His recent publications also explore biomarkers and molecular diagnostics in cancer, particularly related to pancreatic and gastric cancers.

Articles (21)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (4)

Chang Gok Woo

Chungbuk National University Hospital

SOUTH KOREA

View details

Yeon Hee Park

Professor

Sungkyunkwan University

SOUTH KOREA

View details

Jeong Eon Lee

Professor

Samsung Medical Center

SOUTH KOREA

View details

Min-Sang LEE

Soonchunhyang University Hospital Bucheon

SOUTH KOREA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Hongsik Kim

Research Interests

Explore related searches

Contact this professor

About

Articles (21)

Differential diagnosis of synchronous double primary squamous cell carcinomas of the esophagus and occult primary oropharynx through HPV testing: A case report

Discordance in Claudin 18.2 Expression Between Primary and Metastatic Lesions in Patients With Gastric Cancer

Real-World Study of Systemic Treatment after First-Line Atezolizumab plus Bevacizumab for Hepatocellular Carcinoma in Asia-Pacific Countries

Targeted Suppression of CEACAM6 via pHLIP-Delivered RNAs in Pancreatic Ductal Adenocarcinoma

Novel diagnostic biomarkers for pancreatic cancer: assessing methylation status with epigenetic-specific peptide nucleic acid and KRAS mutation in cell-free DNA

Therapeutic Effect of Anti-Inflammatory Tripeptide Cream in Hand-Foot Syndrome/Skin Reaction Related to Anticancer Drugs: a Randomized, Double-Blind, Placebo-Controlled Pilot Trial

Value of glucose transport protein 1 expression in detecting lymph node metastasis in patients with colorectal cancer.

Efficacy of ferric carboxymaltose or darbepoetin alfa for chemotherapy-induced anemia in patients with esophagogastric or pancreaticobiliary cancer: a retrospective comparative study

Synchronous pancreatic adenocarcinoma and duodenal mucosa‑associated lymphoid tissue lymphoma: A case report

Clinical Outcomes of Maintenance Durvalumab After Definitive Concurrent Chemoradiotherapy in Unresectable Locally Advanced Stage III NSCLC According to EGFR and ALK Status: Korean Cancer Study Group LU-22-18

Pembrolizumab-induced psoriatic arthritis treated with disease-modifying anti-rheumatic drugs in a patient with gastric cancer: A case report.

Long-Term Breast Cancer Outcomes of Pregnancy-Associated Breast Cancer (PABC) in a Prospective Cohort

The new diagnostic criteria for myelodysplasia-related acute myeloid leukemia is useful for predicting clinical outcome: comparison of the 4th and 5th World Health Organization classifications

Neoadjuvant Nivolumab plus Gemcitabine/Cisplatin Chemotherapy in Muscle-Invasive Urothelial Carcinoma of the Bladder

EGFR Mutation-Positive Unresectable Stage III Non-Squamous Lung Cancer is Associated with a High Incidence of Brain Metastasis

Expression of PD-L1 as a predictive marker of sensitivity to immune checkpoint inhibitors in patients with advanced biliary tract cancer

A Retrospective Study of First-Line Therapy Involving Immune Checkpoint Inhibitors in Patients With Poor Risk Metastatic Renal Cell Carcinoma.

Osimertinib Combined with Systemic Chemotherapy for EGFR Mutant, T790M-Negative, Non-Small Cell Lung Cancer Patients Who Develop Leptomeningeal Metastases with Extracranial Progression to Prior EGFR TKI.

A Comparison of Folinic Acid, Fluorouracil and Irinotecan (FOLFIRI) plus Bevacizumab and FOLFIRI plus Aflibercept as Second-line Treatment for Metastatic Colorectal Cancer.

HER2 Aberrations as a Novel Marker in Advanced Biliary Tract Cancer

Real-World Evidence of Trastuzumab, Pertuzumab, and Docetaxel Combination as a First-Line Treatment for Korean Patients with HER2-Positive Metastatic Breast Cancer.

Collaborators (4)

Chang Gok Woo

Yeon Hee Park

Jeong Eon Lee

Min-Sang LEE

Make your next move.